What's Happening?
Manufacturers of cell-containing products are developing new techniques to navigate unclear regulatory guidance on particulates. According to Diana Colleluori, PhD, a principal chemistry, manufacturing, and controls consultant at Biologics Consulting,
these products are difficult to visually inspect due to their opaque storage bags and the presence of cells. The particulates, primarily plastic, enter the product from single-use equipment during manufacturing. To address this, companies are testing the process with a formulation buffer minus the cells, allowing for clearer assessment of particulates. This method helps ensure that product contact materials meet regulatory limits. Quality control tests, including those based on United States Pharmacopeia chapters, are conducted on small samples of the final product. The choice of tests depends on the method of administration, with stricter regulations for certain types of injections.
Why It's Important?
The development of new techniques to manage particulates in cell-containing products is crucial for the biotech industry, which faces significant regulatory challenges. Ensuring compliance with particulate regulations is vital for maintaining product safety and efficacy, which in turn affects the industry's ability to bring innovative therapies to market. This has broader implications for public health, as it impacts the availability of advanced medical treatments. Companies that successfully navigate these challenges can gain a competitive edge, potentially leading to increased market share and profitability. Moreover, advancements in this area could set new industry standards, influencing regulatory policies and practices globally.
